Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | CSGALNACT1 | Q8TDX6 | 5/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041988 | 1.00 | POLB (0.37) | POLBMMETACR3CSGALNACT1ABCG2 | |
| SCHEMBL23041654 | 0.97 | POLB (0.38) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL29452788 | 0.97 | POLB (0.38) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL23052230 | 0.97 | POLB (0.38) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL23041655 | 0.97 | POLB (0.38) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL23041653 | 0.97 | POLB (0.38) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL23041643 | 0.91 | POLB (0.35) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL23041682 | 0.91 | POLB (0.35) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL23041645 | 0.91 | POLB (0.35) | POLBMMETACR3ABCG2MMP13 | |
| SCHEMBL23041644 | 0.91 | POLB (0.35) | POLBMMETACR3ABCG2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | claimed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | claimed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |